Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer.
Cerbelli B, Scagnoli S, Mezi S, De Luca A, Pisegna S, Amabile MI, Roberto M, Fortunato L, Costarelli L, Pernazza A, Strigari L, Della Rocca C, Marchetti P, d'Amati G, Botticelli A. Cerbelli B, et al. Among authors: pisegna s. Cancers (Basel). 2020 Sep 16;12(9):2648. doi: 10.3390/cancers12092648. Cancers (Basel). 2020. PMID: 32947953 Free PMC article.
Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
Mazzotta M, Pizzuti L, Krasniqi E, Di Lisa FS, Cappuzzo F, Landi L, Sergi D, Pelle F, Cappelli S, Botti C, Vizza E, Tomao S, Marchetti L, Sanguineti G, Botticelli A, Marchetti P, Magri V, Pisegna S, Venuti A, Tomao F, Buzzacchino F, Ciliberto G, Barba M, Vici P. Mazzotta M, et al. Among authors: pisegna s. Cancers (Basel). 2021 Aug 12;13(16):4061. doi: 10.3390/cancers13164061. Cancers (Basel). 2021. PMID: 34439215 Free PMC article. Review.
Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments.
Nicolazzo C, Gelibter A, Bottillo I, Belardinilli F, Pisegna S, De Renzi G, Marinelli D, Grammatico P, Cortesi E, Giannini G, Gazzaniga P. Nicolazzo C, et al. Among authors: pisegna s. Diagnostics (Basel). 2021 Nov 25;11(12):2196. doi: 10.3390/diagnostics11122196. Diagnostics (Basel). 2021. PMID: 34943432 Free PMC article.
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Botticelli A, Pomati G, Cirillo A, Scagnoli S, Pisegna S, Chiavassa A, Rossi E, Schinzari G, Tortora G, Di Pietro FR, Cerbelli B, Di Filippo A, Amirhassankhani S, Scala A, Zizzari IG, Cortesi E, Tomao S, Nuti M, Mezi S, Marchetti P. Botticelli A, et al. Among authors: pisegna s. Front Immunol. 2022 Nov 3;13:974087. doi: 10.3389/fimmu.2022.974087. eCollection 2022. Front Immunol. 2022. PMID: 36405727 Free PMC article.
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Botticelli A, Cirillo A, Pomati G, Cortesi E, Rossi E, Schinzari G, Tortora G, Tomao S, Fiscon G, Farina L, Scagnoli S, Pisegna S, Ciurluini F, Chiavassa A, Amirhassankhani S, Ceccarelli F, Conti F, Di Filippo A, Zizzari IG, Napoletano C, Rughetti A, Nuti M, Mezi S, Marchetti P. Botticelli A, et al. Among authors: pisegna s. Cancer Immunol Immunother. 2023 Jul;72(7):2217-2231. doi: 10.1007/s00262-023-03384-9. Epub 2023 Mar 3. Cancer Immunol Immunother. 2023. PMID: 36869232 Free PMC article.
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey.
Cerbelli B, Cirillo A, Pomati G, Pernazza A, Ascione A, Pisegna S, Pisano A, Leopizzi M, Pignataro MG, Costarelli L, Mulè A, Vecchione A, Catalano P, Coppola L, Perrone G, Perracchio L, Anemona L, Mastracchio A, Nardi S, Reitano R, Massari A, Grillo LR, Liberati F, Della Rocca C, Marchetti P, Botticelli A, D'Amati G. Cerbelli B, et al. Among authors: pisegna s. Tumori. 2024 Feb;110(1):44-48. doi: 10.1177/03008916231196781. Epub 2023 Sep 19. Tumori. 2024. PMID: 37726962
The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.
Mezi S, Botticelli A, Scagnoli S, Pomati G, Fiscon G, De Galitiis F, Di Pietro FR, Verkhovskaia S, Amirhassankhani S, Pisegna S, Gentile G, Simmaco M, Gohlke B, Preissner R, Marchetti P. Mezi S, et al. Among authors: pisegna s. Cancers (Basel). 2023 Sep 15;15(18):4587. doi: 10.3390/cancers15184587. Cancers (Basel). 2023. PMID: 37760556 Free PMC article.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Botticelli A, et al. Among authors: pisegna s. Oncologist. 2024 Apr 4;29(4):303-310. doi: 10.1093/oncolo/oyad308. Oncologist. 2024. PMID: 37995313 Free PMC article.
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort.
Ceccarelli F, Natalucci F, Picciariello L, Cirillo A, Olivieri G, Veroli M, Pisegna S, Ciancarella C, Gelibter A, Picone V, Santini D, Botticelli A, Conti F. Ceccarelli F, et al. Among authors: pisegna s. Clin Exp Med. 2024 Apr 10;24(1):72. doi: 10.1007/s10238-024-01317-z. Clin Exp Med. 2024. PMID: 38598028 Free PMC article.
20 results